SCHEMBL4677919

SCHEMBL4677919

O=C(O)/C(O)=C/C(=O)c1ccoc1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
CYP3A4 P08684 1/20 0.39
MAPK1 P28482 1/20 0.39
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
BRAF P15056 1/20 0.34
NAMPT P43490 1/20 0.33
MAPT P10636 1/20 0.33
FLT1 P17948 2/20 0.33
FLT4 P35916 2/20 0.33
KDR P35968 2/20 0.33
MAOB P27338 1/20 0.32
POLB P06746 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677921 1.00 ALDH1A1 (0.39) ALDH1A1CYP3A4MAPK1AKR1C3AKR1C2
SCHEMBL4671304 0.88 PTGS2 (0.36) ALDH1A1AKR1C3AKR1C2AKR1C1BRAF
SCHEMBL4671306 0.88 PTGS2 (0.36) ALDH1A1AKR1C3AKR1C2AKR1C1BRAF
SCHEMBL4670853 0.88 HTR6 (0.36) ALDH1A1MAPK1KMT2AMEN1NAMPT
SCHEMBL4670850 0.88 HTR6 (0.36) ALDH1A1MAPK1KMT2AMEN1NAMPT
SCHEMBL4674289 0.79 ALDH1A1 (0.39) ALDH1A1CYP3A4MAPK1AKR1C3AKR1C2
SCHEMBL4674294 0.79 ALDH1A1 (0.39) ALDH1A1CYP3A4MAPK1AKR1C3AKR1C2
SCHEMBL4672962 0.77 ALDH1A1 (0.40) ALDH1A1CYP3A4MAPK1AKR1C3AKR1C2
SCHEMBL4672968 0.77 ALDH1A1 (0.40) ALDH1A1CYP3A4MAPK1AKR1C3AKR1C2
SCHEMBL4675358 0.77 ALDH1A1 (0.31) ALDH1A1CYP3A4MAPK1KMT2ANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885CYP3A4 4/4885MAPK1 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.